|
|
- The Leukemia &
Lymphoma Society's Team In Training® is the world's largest
endurance sports training program. The program provides training
to run or walk marathons and half marathons or participate
in triathlons and century (100-mile) bike rides. Since 1988,
more than 360,000 volunteer participants have helped raise
more than $850 million. Click
hre for more information.
- Dr. Nick
Padron is a physician who has multiple myeloma. Dr. Padron
has, from diagnosis, been looking for a better answer than
the typical treatments available for myeloma. His search led
him to Johns Hopkins University where he found researchers
working on treating the Myeloma Stem Cell, the precursor cell
that is believed to create all the myeloma cells that represent
our cancer.
Dr. Padron has acquired a drug that is not yet available to
the general public and has been using that drug in what he
hopes will provide a cure for him. His presentation was entitled:
Myeloma Cancer Stem Cell
- Dr. Charles
(Chuck) Wakefield is the Director of the Advanced Education
in General Dentistry Program at the Baylor College of Dentistry
(BCD) in Dallas. Dr. Wakefield also happens
to have multiple myeloma and is a patient of Dr. Brian Berryman.
- Dr. Wakefield has written
the professional protocol for dental care for those taking
oral and IV bisphosphonates (such as Aredia and Zometa),
as he recognizes that the problem of Osteonecrosis of the
Jaw (ONJ) is a very serious problem for all of us with myeloma.
Click here for Dr. Wakefield’s article.
- Your
North Texas Myeloma Support Group was, once again, honored
to have Dr. Brian Berryman present to us at our September
8th meeting. His presentation was entitled: Transplantation
and Multiple Myeloma. We were also honored to have Laura
Brougher, Transplant Coordinator, who talked about “Side
Effects of Transplantation and Treatment.” Many of our
members already knew Dr. Berryman and Laura from their transplant
experiences at either Baylor or Medical City. Here
is Dr. Berryman's presentation
- This
is a four-part series of articles on bone marrow and stem
cell transplantation. The series will prepare you to ask
your transplant team meaningful questions and help you to
understand the answers. This article provides an overview
of bone marrow and stem cell transplantation and explains
the differences between autologous and allogeneic transplants.
This four-part series is written by Edward Agura, MD, an advisory
panel member for the PLWC Editorial Board. Dr. Agura is Director
of the Program in Blood and Marrow Transplant at Baylor University
Medical Center in Dallas, TX.
- Testing
History Template: Have you wondered which
of your laboratory test results to track or how best to track
them? Wonder no more. Developed by our own Dennis
McClure, these templates will help you organize and record
your test results that you should track as a Myeloma Survivor.
There are two types of tools:
1. Automated
MS-Excel Spreadsheet Tool - Contains automated
formulas and automatically creates trend line charts
for some of the more important tests. Trends are usually
more relevant than individual test results. The "Directions
For Use" should answer most questions and provides
suggestions. All versions of the MS-Excel tools can
be personalized and customized (see "Directions
For Use") before printing to fit each patient better
(To open/save
these to your machine, please right click on each link
and do a "Save Target As". Once saved on your
machine, you can open it using Word or Excel)
|
2.
Manual Use Forms - Don't have a computer or
know how to use MS-Excel? Have a family member, friend,
or support group member print out a supply of Manual
Use Forms to fill in with pencil or pen. While the MS-Excel
version of this manual use form can be personalized
and customized before printing to fit each patient better,
the PDF forms can not be modified.
(To
open/save these to your machine, please right click
on each link and do a "Save Target As". Once
saved on your machine, you can open it using Excel or
PDF Reader)
|
If you encounter any problem
with downloading these files, please e-mail Yelak.
If you have any problems with the template itself and/or have
any questions related to the template, please e-mail Dennis.
- Patrick Beal introduced Dr.
Berryman to us, although few, if any, of us were unfamiliar
with our favorite myeloma doctor. The presentation
was interesting on many fronts, including the rapid progression
of scientific advances in cytogenetics both for prognostic
value as well as determining treatment choices.
Beside the frontline single or tandem stem cell transplant
choices, many studies are being done on chemo combinations
that include Velcade or Revlimid, as well as thalidomide.
Dr. Berryman went through all of the standard treatments,
at this time, leaving some of the more exotic agents for a
future presentation. Remember that we will have Dr. Berryman
with us again in September; at that time, we will have the
larger Beasley Auditorium on the floor above our usual meeting
room.
Our group gave Dr. Berryman a well-deserved round of applause
when he concluded. We are so very grateful that he is willing
to take time out of his weekend to bring us this important
information. He also answered quite a few questions from the
floor before we allowed him to escape.
- On November 9, 2006, the IMF
held a conference call discussing Medicare
Part D: Patient Access and Facilitating Patient Access to
Novel Therapies in Myeloma. These
are the slides that were used during the conference call.
In order to enable you to take advantage of the information
shared at the conference call, the IMF has arranged for a
digital recording which will be available for replay. The
dates that this call will be available are from November 9,
2006 at 1:30 p.m. (CST) through December 9, 2006 11p.m. (CST).
-
To access the recording, please use the Dial-In
Number listed below and the
Conference
ID#.
Dial In #: 1-800-642-1687 OR 706-645-9291
Conference ID#: 9963217
- Over
the last few months, the IMF has run a series of conference
calls in an effort to assist patients in understanding the
newly approved drug, lenalidomide (Revlimid®).
- The IMF
also conducted two radio programs in July and August with
"The Group Room"
Cancer Talk Radio Show!
- BANK
ON A CURE™ : During the last decade brilliant scientists mapped the
human genome providing a bridge to understanding human DNA.
During the first decade of this century the International
Myeloma Foundation will cross that bridge by pioneering the
first global Myeloma-specific DNA bank in history:
Bank On A Cure™
|
